McKesson Corporation vs Paycom Software Inc — how do they compare? McKesson Corporation trades at $937.1 (market cap $108.46B), while Paycom Software Inc trades at $231.94 (market cap $10.36B). The key difference: McKesson Corporation is far larger — about 10.5× Paycom Software Inc's market cap, and Paycom Software Inc pays the higher dividend (0.65%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Paycom Software Inc for 84 Days on average.
| MCK | PAYC | |
|---|---|---|
Market Cap | $108.46B | $10.36B |
Volume | 712,607 | 666,294 |
Sector | Health | Technology |
52-Week High | $995.69 | $240.52 |
52-Week Low | $725.17 | $113.59 |
Typical Hold Time | 74 Days | 84 Days |
Enterprise Value | $115.00B | $11.15B |
Dividend Yield | 0.4% | 0.65% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Paycom Software (PAYC) trades at $232.22, up 3.86% today, reflecting strong momentum after recent earnings beats and raised 2026 guidance. The stock shows bullish technical signals, with support near $226 and resistance at $232. Fundamentally, PAYC maintains robust profitability with a 22.78% net margin and 10% revenue growth in Q2 2026, though its P/E of 24.33 suggests a premium valuation. Positive sentiment is driven by institutional buying and analyst coverage, with 47% recommending Buy.
Outlook: PAYC's earnings momentum and operational efficiency support upside, but risks include premium valuation pressure and labor market sensitivity. The consensus price target of $207.75 implies caution, yet raised guidance and buybacks provide tailwinds. Investors should weigh strong execution against macroeconomic headwinds affecting payroll demand.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →